Abstract
Royal jelly is a food for queen and larvae honeybees. 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”) is the principal lipid component in royal jelly. Several pharmacological activities of 10H2DA have been reported: anti-tumor, anti-biotic, immunomodulatory, estrogenic and neurogenic. We recently revealed an inhibitory effect of 10H2DA in innate immune signals. Despite appreciable advances in studies on innate immune signals after the identification of Toll-like receptors as innate immune receptors, few studies have reported the effect of 10H2DA on innate immune signals. In this review, we focus on recent advances in the evaluation of the biological activities of 10H2DA (especially immunomodulatory activities). We also discuss the molecular mechanisms underpinning these biological activities, which could lead to new therapeutic targets for the treatment of immune disorders.
Keywords: Fatty acids, immune disorders, immunomodulator, innate immunity, royal jelly, Toll-like receptors, 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”), propolis, ω-hydroxy lipids, royal jelly protein (MRJP)1, nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), innate and adaptive immunity.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses
Volume: 12 Issue: 4
Author(s): Tsuyoshi Sugiyama, Keita Takahashi and Hiroshi Mori
Affiliation:
Keywords: Fatty acids, immune disorders, immunomodulator, innate immunity, royal jelly, Toll-like receptors, 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”), propolis, ω-hydroxy lipids, royal jelly protein (MRJP)1, nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), innate and adaptive immunity.
Abstract: Royal jelly is a food for queen and larvae honeybees. 10-Hydroxy-trans-2-decenoic acid (10H2DA; “royal jelly acid”) is the principal lipid component in royal jelly. Several pharmacological activities of 10H2DA have been reported: anti-tumor, anti-biotic, immunomodulatory, estrogenic and neurogenic. We recently revealed an inhibitory effect of 10H2DA in innate immune signals. Despite appreciable advances in studies on innate immune signals after the identification of Toll-like receptors as innate immune receptors, few studies have reported the effect of 10H2DA on innate immune signals. In this review, we focus on recent advances in the evaluation of the biological activities of 10H2DA (especially immunomodulatory activities). We also discuss the molecular mechanisms underpinning these biological activities, which could lead to new therapeutic targets for the treatment of immune disorders.
Export Options
About this article
Cite this article as:
Sugiyama Tsuyoshi, Takahashi Keita and Mori Hiroshi, Royal Jelly Acid, 10-Hydroxy-trans-2-Decenoic Acid, as a Modulator of the Innate Immune Responses, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (4) . https://dx.doi.org/10.2174/187153012803832530
DOI https://dx.doi.org/10.2174/187153012803832530 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface [Hot Topic: Marine Natural Products (Guest Editor: Vassilios Roussis)]
Current Medicinal Chemistry The Novel Role for Lyn in Integrin Signaling in Human Disease
Current Signal Transduction Therapy Tyrosine Kinase Inhibitor-Induced Hypertension: Role of Hypertension as a Biomarker in Cancer Treatment
Current Vascular Pharmacology MicroRNA Dysregulation in the Myelodysplastic Syndromes
MicroRNA Progress in the Development of Selective Inhibitors of Aurora Kinases
Current Topics in Medicinal Chemistry Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets Development of Novel Cardiovascular Therapeutics From Small Regulatory RNA Molecules - An Outline of Key Requirements
Current Pharmaceutical Design Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention
Current Drug Targets MicroRNA Therapeutics: The Emerging Anticancer Strategies
Recent Patents on Anti-Cancer Drug Discovery Cinnamic Acid Derivatives in Tuberculosis, Malaria and Cardiovascular Diseases - A Review
Current Organic Chemistry Nanotechnology on Duty in Medical Applications
Current Pharmaceutical Biotechnology Imatinib Mesylate for the Treatment of Solid Tumours: Recent Trials and Future Directions
Current Enzyme Inhibition Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Endothelin Axis: A Novel Target for Pharmacotherapy of Female Malignancies
Current Vascular Pharmacology Novel Approaches to Modulate Apoptosis Resistance: Basic and Clinical Implications in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Current Drug Delivery Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics
Current Medicinal Chemistry Epigenetic Therapies of Cancer
Current Cancer Therapy Reviews Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry Management of Early Stage Chronic Myeloid Leukemia: State-of-the-art Approach and Future Perspectives
Current Cancer Drug Targets Cinnamic Acid Derivatives as Anticancer Agents-A Review
Current Medicinal Chemistry